SAP SE

  • WKN: 716460
  • ISIN: DE0007164600
  • Land: Deutschland

Nachricht vom 12.12.2011 | 15:27

SAP AG: Release according to Article 30e of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


SAP AG  / Third country release according to Article 30e Para. 1, No. 3
of the WpHG [the German Securities Trading Act]

12.12.2011 15:27

Dissemination of a Post-admission Duties announcement according to Article
30e Para. 1 No. 3 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

With ad hoc announcement dated December 3, 2011 SAP AG ('SAP') announced that SAP's subsidiary, SAP America, Inc., has entered into a definitive merger agreement with SuccessFactors, Inc. ('SuccessFactors') pursuant to which a subsidiary of SAP would offer to acquire all outstanding shares of common stock of SuccessFactors. In connection with this merger agreement, SAP has filed on December 9, 2011 with the U.S. Securities and Exchange Commission (SEC) the following documents: A Schedule TO-C including - 'Exhibit (a)(5)(O) - Transcript of Barclays Capital Global Technology Conference held on December 8, 2011' These documents are available on the website of SAP AG under http://www.sap.com/corporate-en/investors/successfactors/offer.epx. 12.12.2011 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: SAP AG Dietmar-Hopp-Allee 16 69190 Walldorf Germany Internet: www.sap.com End of Announcement DGAP News-Service

GBC im Fokus

MagForce AG:

Die kommerzielle Behandlung mit der MagForce-Technologie wird nun auch vom Klinikum Vivantes Friedrichshain abgedeckt. Damit kommt diese neue Technologie bereits in vier Kliniken in Deutschland für die kommerzielle Behandlung bösartiger Hirntumore zum Einsatz, was als eine gute Basis für einen Anstieg der Behandlungsumsätze anzusehen ist. Parallel dazu rechnen wir mit der Marktzulassung zur Behandlung von Prostatakrebs in den USA zum Ende des Geschäftsjahres 2017. Wir vergeben das Rating KAUFEN.

News im Fokus

Deutsche Post AG: Informationen zum Aktienrückkauf - 2. Tranche

27. Mai 2016, 17:05

Aktueller Webcast

windeln.de AG

Q1 2016 Earnings Call

24. Mai 2016

Aktuelle Research-Studie

Edel AG

Original-Research: Edel AG (von Montega AG): Kaufen

26. Mai 2016